Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by SFE Investment Counsel

SFE Investment Counsel reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,016 shares of the company’s stock after selling 481 shares during the period. SFE Investment Counsel’s holdings in Omnicell were worth $1,668,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of OMCL. KB Financial Partners LLC bought a new stake in shares of Omnicell during the first quarter valued at approximately $29,000. Certified Advisory Corp bought a new stake in shares of Omnicell during the first quarter valued at approximately $32,000. Parkside Financial Bank & Trust raised its holdings in Omnicell by 141.0% during the second quarter. Parkside Financial Bank & Trust now owns 294 shares of the company’s stock worth $45,000 after purchasing an additional 172 shares in the last quarter. Harbor Investment Advisory LLC raised its holdings in Omnicell by 22.5% during the second quarter. Harbor Investment Advisory LLC now owns 479 shares of the company’s stock worth $73,000 after purchasing an additional 88 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its holdings in Omnicell by 214.3% during the second quarter. Cullen Frost Bankers Inc. now owns 550 shares of the company’s stock worth $83,000 after purchasing an additional 375 shares in the last quarter.

In other Omnicell news, CFO Peter J. Kuipers sold 11,500 shares of the company’s stock in a transaction dated Friday, August 6th. The shares were sold at an average price of $157.88, for a total transaction of $1,815,620.00. Following the sale, the chief financial officer now directly owns 59,812 shares of the company’s stock, valued at $9,443,118.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Scott Peter Seidelmann sold 41,878 shares of the stock in a transaction dated Thursday, August 5th. The stock was sold at an average price of $153.05, for a total transaction of $6,409,427.90. The disclosure for this sale can be found here. Insiders have sold a total of 96,284 shares of company stock worth $14,728,766 in the last quarter. 2.63% of the stock is owned by corporate insiders.

Shares of NASDAQ OMCL traded down $0.71 during mid-day trading on Wednesday, reaching $157.35. 1,977 shares of the company were exchanged, compared to its average volume of 307,613. The company’s 50-day simple moving average is $153.13 and its 200-day simple moving average is $143.44. The company has a quick ratio of 2.78, a current ratio of 3.10 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $6.84 billion, a P/E ratio of 121.58, a P/E/G ratio of 4.97 and a beta of 1.04. Omnicell, Inc. has a twelve month low of $67.66 and a twelve month high of $162.86.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 29th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.55 by $0.42. Omnicell had a net margin of 6.05% and a return on equity of 11.06%. The firm had revenue of $272.74 million for the quarter, compared to analyst estimates of $267.20 million. As a group, equities research analysts expect that Omnicell, Inc. will post 2.68 EPS for the current year.

Several brokerages recently commented on OMCL. TheStreet raised Omnicell from a “c+” rating to a “b+” rating in a report on Thursday, July 29th. Piper Sandler lifted their price objective on shares of Omnicell from $152.00 to $188.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 23rd. BTIG Research restated a “buy” rating and set a $151.49 price target (down from $165.00) on shares of Omnicell in a report on Tuesday, July 27th. JPMorgan Chase & Co. began coverage on shares of Omnicell in a research note on Wednesday, June 9th. They issued a “neutral” rating and a $146.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating and set a $162.00 price objective for the company. in a research note on Friday, July 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Omnicell currently has an average rating of “Hold” and an average target price of $141.06.

Omnicell Company Profile

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.

Further Reading: How is net asset value different from market price?

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.